Can the effect of antiangiogenic treatments be monitored and quantified noninvasively by using contrast-enhanced US?
Guibal et al (1) have demonstrated that contrast-enhanced US-derived parameters provide a noninvasive measure of tumor angiogenesis and, in particular, of the revascularization occurring after discontinuation of an antivascular endothelial growth factor (anti-VEGF) therapy. If these results can be reproduced in future clinical trials, contrast-enhanced US will enable the accurate monitoring of patient response to antiangiogenic therapies (including treatment suspensions), which should improve clinical outcomes.